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a b s t r a c t
Current drugs against human African trypanosomiasis (HAT) suffer from several serious drawbacks. The
search for novel, effective, brain permeable, safe, and inexpensive antitrypanosomal compounds is there-
fore an urgent need. We have recently reported that the 4-aminoquinoline derivative huprine Y, devel-
oped in our group as an anticholinesterasic agent, exhibits a submicromolar potency against
Trypanosoma brucei and that its homo- and hetero-dimerization can result in to up to three-fold increased
potency and selectivity. As an alternative strategy towards more potent smaller molecule anti-HAT
agents, we have explored the introduction of x-cyanoalkyl, x-aminoalkyl, or x-guanidinoalkyl chains
at the primary amino group of huprine or the simplified 4-aminoquinoline analogue tacrine. Here, we
describe the evaluation of a small in-house library and a second generation of newly synthesized deriva-
tives, which has led to the identification of 13 side chain modified 4-aminoquinoline derivatives with
submicromolar potencies against T. brucei. Among these compounds, the guanidinononyltacrine ana-
logue 15e exhibits a 5-fold increased antitrypanosomal potency, 10-fold increased selectivity, and 100-
fold decreased anticholinesterasic activity relative to the parent huprine Y. Its biological profile, lower
molecular weight relative to dimeric compounds, reduced lipophilicity, and ease of synthesis, make it
an interesting anti-HAT lead, amenable to further optimization to eliminate its remaining anti-
cholinesterasic activity.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Human African trypanosomiasis (HAT or sleeping sickness) is
one of the 17 infectious diseases grouped under the term Neglected
Tropical Diseases, which inflict a devastating effect on the health
and economy of nearly 150 countries.1–4 HAT is caused by two sub-
species of the protozoan parasite Trypanosoma brucei, which are
transmitted to humans through the bite of tsetse flies in rural areas
of sub-Saharan Africa. The two subspecies of this parasite lead to
distinct disease courses and display different geographical distri-
bution. Most cases of HAT occur in western and central Africa
and are due to T. brucei gambiense, which causes a chronic infection
that slowly progresses from an initial hemolymphatic stage, often
asymptomatic, to a late stage, in which the parasites spread into
the central nervous system. This produces severe neurological
pathology, including sleep disruptions, which give rise to the com-
mon name of the disease. About 2–5% of HAT cases occur in south-
ern and eastern Africa and are caused by T. brucei rhodesiense. This
leads to an acute infection that rapidly progresses from early to
late stage disease. With both forms of HAT, the absence of effective
treatment in the late stage inexorably leads to coma and death.5
Over the last 15 years, because of public health measures, there
has been considerable success combatting HAT, with the estimated
numbers of those infected falling from 300,000 to less than
20,000.6 However, the disease still occurs in 36 countries, with
65 million people at risk, and there is a constant potential for large
epidemic outbreaks.
Vaccines are not a realistic option for prevention of HAT
because of antigenic variation in the parasite.7 Chemotherapy is
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therefore of particular importance.8 Unfortunately, the few drugs
that have been approved for HAT (pentamidine and suramin for
early stage HAT; melarsoprol and eflornithine, alone or in combi-
nation with nifurtimox, for late stage HAT) are unsatisfactory for
several reasons, which include the occurrence of major side effects,
high costs associated with parenteral administration and medical
supervision, lack of brain permeability (in the case of pentamidine
and suramin), which precludes their use in late stage HAT, and the
increasing emergence of resistance.9–11 Thus, the development of
novel antitrypanosomal compounds that can overcome these
issues is urgently needed.3,12
Repurposing of known drugs is being increasingly pursued for
antitrypanosomal drug discovery, particularly because this strat-
egy should be more rapid and less expensive than the development
of new chemical entities.4,13–15 Despite this, most research efforts
to replenish the antitrypanosomal pipeline remain focussed on
the development of novel compounds, rationally designed or
screened against one or several parasite biological targets16–19 or,
more often, arising from phenotypic whole cell screens of com-
pound libraries.20–26
7-Chloro-4-aminoquinoline derivatives are within those struc-
tural classes that are being developed for the treatment of HAT.27
We recently reported that huprine Y (1, Fig. 1), a 7-chloro-4-
aminoquinoline derivative with potent acetylcholinesterase
(AChE) inhibitory activity, developed in our group as an anti-Alz-
heimer drug candidate,28 exhibited significant activity against T.
brucei (IC50 = 0.61 lM, selectivity index (SI) over rat myoblast L6
cells = 13).29,30 In 4-aminoquinoline-based antimalarials, both
dimerization and side chain modification have been used to
increase potency and overcome parasite resistance.31–35 Interest-
ingly, we have found that homodimerization of huprine Y (as in
compound 2,36 Fig. 1) and heterodimerization with the 4-amino-
quinoline derivative tacrine (as in compound 3,37 Fig. 1) also
results in up to 3-fold increased potency and selectivity against
T. brucei.
Modification of the side chain attached to the exocyclic amino
group of 7-chloro-4-aminoquinoline derivatives has also been
reported to lead to increased antitrypanosomal activity.35 To
explore further the structure–antitrypanosomal activity relation-
ships around the huprine scaffold, we report here: (i) the screening
of a series of huprine derivatives, substituted at the exocyclic
amino group with cyanoalkyl or aminoalkyl chains of different
lengths and nature (nitriles 4a–h, and amines 5a–h, Fig. 2), against
cultured bloodstream forms of T. brucei, rat skeletal myoblast L6
cells, and electric eel AChE, and the evaluation of their brain per-
meability using an in vitro artificial membrane assay (PAMPA-
BBB); (ii) the synthesis and evaluation of the antitrypanosomal,
cytotoxic, and anticholinesterasic activity and brain permeability
of novel huprine and structurally related tacrine derivatives with
other modified side chains terminating in cyano, primary or cyclic
amino, or guanidino groups.
2. Results and discussion
2.1. Screening of the antitrypanosomal, cytotoxic, and
anticholinesterasic activity and brain permeability of the x-
cyanoalkyl- and x-aminoalkyl-huprines 4a–h and 5a–h
The x-aminoalkyl-huprines 5a–h (Fig. 2) were recently synthe-
sized in our group as immediate precursors of a family of huprine-
based anti-Alzheimer hybrid compounds.38 We inferred that these
compounds might be interesting antitrypanosomal leads based on
two grounds. Firstly, aminoalkylhuprines 5a–h should be diproto-
nated at physiological pH, like pentamidine and other antitry-
panosomal dicationic compounds,39,40 which seemed favourable
for anti-HAT activity. Secondly, we expected that the substitution
of one of the lipophilic 4-aminoquinoline moieties of bis(4-amino-
quinoline) dimers, like 2 and 3 (Fig. 1), by a primary amino group
in aminoalkylhuprines 5a–h would result in a decreased AChE
inhibitory activity, and hence, a lower risk of unwanted cholinergic
side-effects. Indeed, this trend in AChE inhibitory activity has been
reported for a family of dimeric tacrines,41 and can be ascribed to a
less efficient interaction with a secondary binding site of the
enzyme AChE, the so-called peripheral anionic site, when the sec-
ond 4-aminoquinoline moiety of the dimer, bis(7)tacrine, is substi-
tuted by a simple primary amino group.
Because some nitriles have been found to display antitry-
panosomal activity,9,42 we also envisaged the biological screening
of the nitriles 4a–h (Fig. 2), the synthetic precursors of amines
5a–h.38
The x-cyanoalkyl-huprines 4a–h and the x-aminoalkyl-hupri-
nes 5a–h were first screened against the bloodstream form of T.
brucei, the clinically relevant form of the parasite,43 using nifur-
timox and huprine Y as reference compounds. These side chain
modified huprine derivatives displayed low micromolar to submi-
cromolar IC50 values, with all of them being more potent antitry-
panosomal agents than nifurtimox, and a few being slightly more
potent than, or equipotent to, the parent huprine Y (Table 1).
Somewhat unexpectedly, nitriles were found to be in general more
potent than the corresponding amines, especially those featuring
hepta- to nona-methylene side chains (octa- to deca-methylene
side chains in the amines), which were 4–8-fold more potent than
their amine counterparts. A clear trend was found in the
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Figure 1. Structures, trypanocidal (T. brucei) activities, and selectivity indices of
huprine Y, 1, and the oligomethylene-linked homo- and heterodimers 2 and 3.
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Figure 2. Structures of cyanoalkyl- and aminoalkyl-huprines 4a–h and 5a–h.
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antitrypanosomal potency of nitriles 4a–h regarding the length of
the linker, with the potency increasing from n = 5 (4a) to n = 9 (4e),
and then decreasing for the longer homologues 4f and 4g. For the
amines, the highest potency was found for the heptamethylene-
linked derivative 5c. The presence of a p-phenylene ring in the side
chain does not seem to be of particular relevance for the antitry-
panosomal activity, with the p-phenylene-linked nitrile 4h and
amine 5h being equipotent to nitrile 4a and amine 5a with a sim-
ilar side chain length.
Thus, the most interesting side chain modified huprine deriva-
tive was nitrile 4e, which, with an IC50 value against T. brucei of
320 nM (and an IC90 value of 420 nM), was 14-fold more potent
than nifurtimox and 2-fold more potent than huprine Y (7-fold
more potent than huprine Y in terms of the IC90 values), in agree-
ment with the expected increase in antitrypanosomal potency
upon modification of the side chain at the exocyclic amino group.
Interestingly, nitriles 4a–h and amines 5a–h turned out to be
less toxic to rat skeletal myoblast L6 cells than to T. brucei, with
nitriles 4a–h being less cytotoxic than the corresponding amines
5a–h (Table 1), especially nitrile 4e, which displayed a selectivity
index of 25, i.e. 2- and 3.5-fold more than that of the parent hupr-
ine Y and nifurtimox, respectively.
As expected, the introduction of the x-cyanoalkyl and x-ami-
noalkyl chains at the primary amino group of huprine Y led to a
clear decrease in AChE inhibitory activity (up to 500-fold).
Notwithstanding the lower AChE inhibitory potency relative to
the parent huprine Y, nitriles 4a–h and amines 5a–h were more
potent AChE inhibitors than would be desirable in antitrypanoso-
mal agents, with nanomolar IC50 values for electric eel AChE inhi-
bition (Table 1).
Because good brain penetration is necessary for the treatment of
late-stage HAT, the brain permeability of nitriles 4a–h and amines
5a–hwas assessed in vitro through thewell-established parallel arti-
ficialmembrane permeability assay (PAMPA-BBB).45 Aswith the par-
enthuprineY, thepermeabilities ofmostof thesemodifiedanalogues,
through the porcine brain lipid extract used as an artificial blood–
brain barrier (BBB) model, were found to be above the threshold
established for high BBB permeation (CNS+, Pe (106 cm s1) > 5.17,
Table 1). Therefore, these compounds are predicted to be able to cross
the BBB, with nitriles 4a–h being more permeable than the corre-
sponding amines (Table 1), probably due to the dicationic character
of the latter at physiological pH.
Overall, the screening of this small in-house compound library
pointed to neutral cyano or basic primary amino groups at the
end of a side chain of 9 or 7 carbon atoms, respectively, as being
favourable substitution patterns for potent, selective, and brain
permeable antitrypanosomal agents.
2.2. Synthesis of novel side chain modified 4-aminoquinoline
derivatives
Even though the x-aminoalkyl-huprines 5a–h turned out to be
less potent antitrypanosomal agents than the corresponding
nitriles 4a–h, they still displayed a submicromolar antitrypanoso-
mal potency in some cases, as well as some selectivity and brain
permeability. Indeed, other classes of compounds, such as bis-
guanidines and bis-amidines, are diprotonated at physiological
pH, like aminoalkylhuprines 5a–h, and exhibit potent antitry-
panosomal activity,40,46–49 and brain permeability.40 To further
extend the SAR around side chain modified huprine derivatives,
we undertook the synthesis and biological profiling of novel diba-
sic huprine derivatives featuring a terminal guanidine (6b and 6e,
Scheme 1), piperidine (7, Scheme 2) or morpholine (8, Scheme 2)
moiety, together with different side chain lengths.
Table 1
Antitrypanosomal, cytotoxic, and anticholinesterasic activity and BBB permeability of cyanoalkylhuprines 4a–h and aminoalkylhuprines 5a–h and reference compounds 1 and
nifurtimoxa
Compd T. brucei IC50 (lM) T. brucei IC90 (lM) L6 cells IC50 (lM) SITbb EeAChE IC50 (nM) Pe (106 cm s1)c (prediction)
4a 2.13 ± 0.49 4.04 ± 0.06 20.3 ± 0.2 9.7 26.9 ± 1.1 d
4b 1.60 ± 0.13 3.21 ± 0.32 19.0 ± 0.3 11.9 31.1 ± 3.1 12.4 ± 0.6 (CNS+)
4c 0.86 ± 0.05 1.22 ± 0.03 11.6 ± 3.0 13.5 d d
4d 0.62 ± 0.02 0.85 ± 0.01 7.65 ± 0.41 12.3 d d
4e 0.32 ± 0.01 0.42 ± 0.01 8.04 ± 0.53 25.1 d d
4f 0.46 ± 0.01 0.61 ± 0.01 4.79 ± 0.25 10.4 9.67 ± 0.89 11.3 ± 1.2 (CNS+)
4g 1.37 ± 0.06 1.91 ± 0.02 4.98 ± 0.21 3.6 d 16.2 ± 1.3 (CNS+)
4h 1.86 ± 0.08 3.39 ± 0.15 10.0 ± 0.8 5.4 158 ± 21 19.3 ± 1.2 (CNS+)
5a 0.92 ± 0.08 2.92 ± 0.43 3.82 ± 0.11 4.2 d d
5b 2.03 ± 0.10 3.09 ± 0.21 4.78 ± 0.16 2.4 d d
5c 0.68 ± 0.20 1.15 ± 0.05 4.33 ± 0.08 6.4 36.0 ± 3.5 7.6 ± 0.7 (CNS+)
5d 2.28 ± 0.29 4.28 ± 0.46 12.5 ± 3.3 5.5 17.3 ± 1.2 9.8 ± 0.6 (CNS+)
5e 2.61 ± 0.16 4.58 ± 0.31 13.6 ± 3.4 5.2 16.4 ± 1.8 7.1 ± 0.7 (CNS+)
5f 3.33 ± 0.10 4.33 ± 0.18 7.55 ± 0.19 2.3 20.3 ± 2.5 7.0 ± 0.3 (CNS+)
5g 1.79 ± 0.03 2.24 ± 0.04 8.06 ± 0.63 4.5 35.3 ± 3.9 4.0 ± 0.2 (CNS±)
5h 0.92 ± 0.03 1.44 ± 0.15 4.27 ± 0.13 4.6 d 11.7 ± 1.1 (CNS+)
1e 0.61 ± 0.03 2.94 ± 0.20 7.80 ± 0.47 13 0.30 ± 0.01 23.8 ± 2.7 (CNS+)f
Nifurtimox 4.4 ± 0.7g 32.0 ± 1.1 7.3 d d
a In vitro activity against bloodstream form of T. brucei (pH 7.4), rat myoblast L6 cells, and Electrophorus electricus AChE, expressed as the concentration that inhibited
growth or enzyme activity by 50% (IC50) and 90% (IC90, for T. brucei). Data are the mean of triplicate experiments ± SEM.
b SITb: selectivity index as the ratio of cytotoxic to anti-T. brucei IC50 values.
c Permeability values from the PAMPA-BBB assay. Values are expressed as the mean ± SD of three independent experiments.
d Not determined.
e Trypanocidal and cytotoxicity activity values taken from Ref. 29.
f Taken from Ref. 38.
g Taken from Ref. 44.
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Scheme 1. Reagents and conditions: (a) 1H-pyrazole-1-carboxamidine hydrochlo-
ride, Et3N, CH3CN, reflux, overnight.
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In addition, to assess the role of the unsaturated methyl-
substituted three-carbon bridge of the huprine moiety, we also
synthesised a series of x-cyanoalkyl-, x-aminoalkyl-, and
x-guanidinoalkyl derivatives (11c, 11e, 12c–e, 13c, 13e, 14e, 15c,
15e, 16e, Scheme 3), in which the huprine core was substituted
by the simpler, less lipophilic (by around 2logP units), and
easier-to-synthesize tricyclic core of the 4-aminoquinoline deriva-
tives tacrine and 6-chlorotacrine (9 and 10, respectively, Scheme 3).
These featured oligomethylene chains of lengths in the range that
was found optimal for antitrypanosomal activity in the huprine
series (n = 7–9).
Guanidinoalkyl huprines 6b and 6e were readily synthesized in
moderate yield (30% and 59%, respectively) from the corresponding
amines 5b and 5e upon reaction with 1H-pyrazole-1-carboxam-
idine hydrochloride in dry CH3CN in the presence of Et3N
(Scheme 1).
Likewise, the synthesis of the piperidinopropyl- and mor-
pholinopropyl-huprines 7 and 8 only required one step, i.e. the
alkylation of huprine Y, 1, with the commercial 1-(3-chloro-
propyl)piperidine hydrochloride or the readily available 3-mor-
pholinopropyl methanesulfonate,50 after deprotonation of the
primary amino group with KOH (Scheme 2).
For the synthesis of the novel cyanoalkyl tacrines 11c, 11e, and
12c–e, the known aminoalkyl tacrines 13c,41 13e,51 and 14e,52 and
the novel guanidinoalkyl tacrines 15c, 15e, and 16e, we followed
the same three-step protocol that we had used in the huprine ser-
ies, based on the initial alkylation of tacrine or chlorotacrine with
the corresponding x-bromoalkanenitrile, followed by LiAlH4
reduction of the cyano to a primary amino group, and final
conversion of the amines into the guanidines upon treatment with
1H-pyrazole-1-carboxamidine hydrochloride (Scheme 3).
All the target compounds were transformed into the corre-
sponding hydrochloride or dihydrochloride salts, with which their
chemical and biological characterization was performed.
2.3. Biological profiling of the novel side chain modified 4-
aminoquinoline derivatives
The therapeutic potential of the second generation side chain
modified huprine and tacrine derivatives was assessed by evalua-
tion of their antitrypanosomal activity against cultured blood-
stream forms of T. brucei, and by their brain permeability.
Additionally, their potential toxicity was assessed by measuring
their effect on the viability of rat L6 cells as a model of normal
mammalian cells and by their AChE inhibitory activity.
We found several compounds that exhibited nanomolar antitry-
panosomal IC50 and IC90 values, favourable selectivity indices, and
brain permeability (Table 2).
With the huprine derivatives, we found that the introduction of
a guanidine at the end of the side chain led to increased antitry-
panosomal potencies relative to the corresponding primary amine
counterparts, and to roughly equipotent activity relative to the
nitriles. Thus, the novel guanidine 6e, with a total of 9 carbon
atoms in the side chain, displayed the same antitrypanosomal
potency as the most active compound of the initially screened ser-
ies, nitrile 4e (IC50 0.3 lM) (Table 2). The introduction of a piperi-
dino or a morpholino substituent at the side chain of the huprine
derivatives 7 and 8 did not seem to confer any particular contribu-
tion to the antitrypanosomal properties, with these compounds
displaying similar activities to several of the aminoalkylhuprines.
The same trend observed with the huprine derivatives in regard
of the terminal functionality and length of the side chain was found
in the tacrine derivatives. The order of antitrypanosomal potencies
was guanidines > nitriles > amines, with higher potencies for the
guanidines and nitriles that have a total number of 9 carbon atoms
in the side chain. Higher antitrypanosomal potencies were also
found for those derivatives with an unsubstituted tacrine moiety.
Thus, the nonamethylene-linked guanidine 15e (IC50 120 nM)
was found to be the most potent side chain modified tacrine
derivative (Table 2).
With regard to the 4-aminoquinoline core, replacement of the
huprine with the less complex tacrine moiety led, in general, to a
drop in antitrypanosomal activity, with x-aminoalkyl- and x-cya-
noalkyl (6-chloro)tacrines being 1–3-fold and 3–9-fold, respec-
tively, less potent than the corresponding x-aminoalkyl- and x-
cyanoalkyl huprine derivatives. A notable exception was the x-
guanidinononyl tacrine 15e, which was 3-fold more potent than
thex-guanidinononyl huprine 6e. Overall this was the most potent
side chain modified 4-aminoquinoline derivative.
Interestingly, all the second generation side chain modified
huprine and tacrine derivatives could be inferred to be capable of
entering the central nervous system (with the sole exception of
guanidine 6b), on the basis of their measured PAMPA-BBB perme-
abilities. All of them, with the exception of 15c, also turned out to
be less toxic to mammalian L6 cells than to T. brucei, with selectiv-
ity indices ranging from 3 to 133 (Table 2). Unfortunately, as with
the first generation of screened compounds, despite inhibiting
AChE 35–180-fold less potently than the parent compound huprine
Y, the anticholinesterasic activity of the second generation side
chain modified huprine and tacrine derivatives was still not ideal.
Their anticholinesterasic activity was 1–2 orders of magnitude
higher than their antitrypanosomal potencies, with the guanidi-
nononyl tacrine 15e being the best balanced compound (with the
anticholinesterasic activity only 4-fold greater than that against
typanosomes).
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Scheme 2. Reagents and conditions: (a) KOH, 4 Å molecular sieves, DMSO, rt, 2 h;
then, 1-(3-chloropropyl)piperidine hydrochloride or 3-morpholinopropyl methane-
sulfonate, DMSO, rt, overnight.
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3. Conclusion
We recently found that both homodimerization and
heterodimerization of the 4-aminoquinoline derivative huprine Y
results in increased potency against T. brucei and improved selec-
tivity over mammalian cells relative to the parent compound,36,37
albeit at the expense of increasing lipophilicity and molecular
weight. In this current paper, we have explored the effect on antit-
rypanosomal activity of the introduction of a side chain, featuring a
terminal cyano, amino, or guanidino group, at the primary amino
group of huprine Y or the simpler structurally related tacrine or
6-chlorotacrine, as an alternative approach to improve the antitry-
panosomal profile. We found that the introduction of a guanidino
or a cyano group at the end of a chain of nine carbon atoms was
the best type of substitution to produce good antitrypanosomal
activity in both the huprine and the tacrine series. The presence
of the tetracyclic huprine core leads to higher antitrypanosomal
potency in the cyanoalkyl derivatives, whereas the opposite trend
was found for guanidinoalkyl derivatives, with the guanidi-
nononyltacrine analogue 15e being the most promising compound
of the side chain modified 4-aminoquinoline derivatives. Overall,
13 out of the 31 side chain modified 4-aminoquinoline derivatives
displayed submicromolar potencies against cultured bloodstream
form T. brucei and good brain permeability. The antitrypanosomal
potency of these compounds is greater than their toxicity to mam-
malian cells, but lower than their anticholinesterasic activity,
which might result in undesirable cholinergic side effects.
Guanidinononyltacrine 15e emerges as the most interesting
antitrypanosomal lead of this class. It is endowed with potent
(IC50 = 120 nM) and selective (SI = 133) activity against T. brucei,
should be brain permeable, and has the least unfavourable antitry-
panosomal/anticholinergic activity ratio. This compound has 5-fold
increased antitrypanosomal potency, 10-fold increased selectivity
index, and 100-fold decreased anticholinesterasic activity com-
pared with the parent huprine Y, together with lower lipophilicity
and molecular weight relative to huprine-based homo- and hetero-
dimeric compounds. Our findings confirm that introduction of a
conveniently functionalized side chain at the primary amino group
of 4-aminoquinoline derivatives may be superior to homo- and
hetero-dimerization as a strategy to improve the potential anti-
HAT therapeutic profile of this structural class.
4. Experimental
4.1. Chemistry. General methods
Melting points were determined in open capillary tubes with a
MFB 595010M Gallenkamp melting point apparatus. 400 MHz
1H/100.6 MHz 13C NMR spectra were recorded on a Varian Mer-
cury 400 spectrometer at the Centres Científics i Tecnològics of
the University of Barcelona (CCiTUB). The chemical shifts are
reported in ppm (d scale) relative to solvent signals (CD3OD at
3.31 and 49.0 ppm in the 1H and 13C NMR spectra, respectively),
and coupling constants are reported in Hertz (Hz). The syn (anti)
notation of the protons at position 13 of the huprine moiety of
compounds 6b,e, 7, and 8 means that the corresponding proton
at position 13 is on the same (different) side of the quinoline
moiety with respect to the cyclohexene ring. IR spectra were
run on a Perkin-Elmer Spectrum RX I spectrophotometer. Absorp-
tion values are expressed as wavenumbers (cm1); only signifi-
cant absorption bands are given. Column chromatography was
performed on silica gel 60 AC.C (35–70 mesh, SDS, ref
2000027). Thin-layer chromatography was performed with alu-
minium-backed sheets with silica gel 60 F254 (Merck, ref.
1.05554), and spots were visualized with UV light and 1% aque-
ous solution of KMnO4. High resolution mass spectra were car-
ried out at the CCiTUB with a LC/MSD TOF Agilent Technologies
spectrometer. The analytical samples of all of the compounds
that were subjected to pharmacological evaluation were dried
at 65 C/2 Torr for at least 2 days (standard conditions). Nitriles
11c and 12c are protected in a patent of our group,53 where,
however, no NMR spectra data were given. A more consistent
chemical characterization of these compounds is included in this
section.
Table 2
Antitrypanosomal, cytotoxic, and anticholinesterase activity and BBB permeability of the N-cyanoalkyl, N-aminoalkyl, and N-guanidinoalkyl 4-aminoquinoline derivatives 6b,e, 7,
8, 11c,e, 12c–e, 13c,e, 14e, 15c,e, and 16e and reference compounds 1 and nifurtimoxa
Compd T. brucei IC50 (lM) T. brucei IC90 (lM) L6 cells IC50 (lM) SITbb EeAChE IC50 (nM) Pe (106 cm s1)c (prediction)
6b 1.37 ± 0.02 1.54 ± 0.01 21.0 ± 1.6 15.3 11.8 ± 1.3 2.9 ± 0.4 (CNS±)
6e 0.33 ± 0.06 0.70 ± 0.09 10.9 ± 0.9 33 10.6 ± 0.8 5.4 ± 0.3 (CNS+)
7 0.83 ± 0.04 1.70 ± 0.21 2.40 ± 0.19 2.9 48.4 ± 2.7 5.9 ± 0.4 (CNS+)
8 1.75 ± 0.19 4.88 ± 0.27 14.3 ± 0.5 8.2 13.3 ± 0.8 15.0 ± 1.0 (CNS+)
11c 3.81 ± 1.13 10.3 ± 2.7 34.8 ± 1.6 9.1 53.9 ± 3.0 11.2 ± 0.2 (CNS+)
11e 0.98 ± 0.05 1.38 ± 0.09 5.73 ± 0.16 4.2 44.9 ± 1.6 7.6 ± 0.35 (CNS+)
12c 7.92 ± 0.17 12.2 ± 0.2 34.7 ± 0.6 4.4 d 16.7 ± 0.9 (CNS+)
12d 6.89 ± 0.13 8.75 ± 0.24 27.8 ± 1.6 4.0 46.0 ± 6.0 14.7 ± 0.8 (CNS+)
12e 1.57 ± 0.17 2.56 ± 0.07 8.00 ± 0.44 5.1 24.3 ± 4.5 5.4 ± 0.4 (CNS+)
13c 2.13 ± 0.05 3.12 ± 0.14 7.28 ± 0.86 3.4 23.9 ± 2.6 7.4 ± 0.1 (CNS+)
13e 4.07 ± 0.12 5.55 ± 0.10 16.6 ± 0.6 4.1 15.6 ± 1.5 6.9 ± 0.5 (CNS+)
14e 2.31 ± 0.36 4.88 ± 0.18 7.62 ± 0.81 3.3 14.5 ± 1.6 5.8 ± 0.3 (CNS+)
15c 0.85 ± 0.09 1.30 ± 0.20 <1.20 <1.4 23.9 ± 2.6 5.9 ± 0.3 (CNS+)
15e 0.12 ± 0.01 0.25 ± 0.04 15.9 ± 0.8 133 30.5 ± 1.9 6.5 ± 0.3 (CNS+)
16e 0.63 ± 0.08 0.96 ± 0.02 11.9 ± 1.2 19 16.4 ± 1.5 6.7 ± 0.4 (CNS+)
1e 0.61 ± 0.03 2.94 ± 0.20 7.80 ± 0.47 13 0.30 ± 0.01 23.8 ± 2.7 (CNS+)f
Nifurtimox 4.4 ± 0.7g 32.0 ± 1.1 7.3 d d
a In vitro activity against bloodstream form of T. brucei (pH 7.4), rat myoblast L6 cells, and Electrophorus electricus AChE, expressed as the concentration that inhibited
growth or enzyme activity by 50% (IC50) and 90% (IC90, for T. brucei). Data are the mean of triplicate experiments ± SEM.
b SITb: selectivity index as the ratio of cytotoxic to anti-T. brucei IC50 values.
c Permeability values from the PAMPA-BBB assay. Values are expressed as the mean ± SD of three independent experiments.
d Not determined.
e Trypanocidal and cytotoxicity activity values taken from Ref. 29.
f Taken from Ref. 38.
g Taken from Ref. 44.
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4.1.1. 1-{6-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-
methanocycloocta[b]quinolin-12-yl)amino]hexyl}guanidine
(6b)
To a solution of amine 5b (462 mg, 1.20 mmol) in dry CH3CN
(5 mL), anhydrous Et3N (0.5 mL, 363 mg, 3.59 mmol) and 1H-pyra-
zole-1-carboxamidine hydrochloride (172 mg, 1.17 mmol) were
added. The reaction mixture was stirred under reflux overnight.
The resulting precipitated solid was taken in CH2Cl2 (25 mL) and
treated with 2 N NaOH (20 mL). The organic phase was washed
with H2O (3  20 mL), dried over anhydrous Na2SO4, and concen-
trated under reduced pressure to afford guanidine 6b (150 mg,
30% yield), as a brownish solid.
A solution of 6b (150 mg, 0.39 mmol) in CH2Cl2 (10 mL) was
treated with a methanolic solution of HCl (0.75 N, 4.2 mL,
3.15 mmol) and concentrated under reduced pressure. The result-
ing solid was taken in MeOH (0.25 mL) and precipitated by addi-
tion of EtOAc (1.4 mL). The precipitate was washed with pentane
(3  2 mL) to give, after drying under standard conditions, 6b2HCl
(37 mg) as a brownish hygroscopic solid; mp 166–168 C; IR (ATR)
m 3500–2500 (max at 3260, 3134, 2929, 2865, +NH, NH, CH st),
1659, 1631, 1582, 1567, 1514 (C@N, Ar–C–C, Ar–C–N st) cm1;
1H NMR (400 MHz, CD3OD) d 1.42–1.54 (complex signal, 4H, 3-
H2, 4-H2), 1.58 (s, 3H, 90-CH3), superimposed in part 1.62 (tt,
J = J0 = 6.8 Hz, 2H, 2-H2), superimposed in part 1.91 (tt,
J = J0 = 7.2 Hz, 2H, 5-H2), 1.93 (br d, J = 17.2 Hz, 1H, 100-Hendo),
superimposed in part 1.94 (br d, J = 12.8 Hz, 1H, 130-Hsyn), 2.09
(dm, J = 12.8 Hz, 1H, 130-Hanti), 2.56 (dd, J = 17.2 Hz, J0 = 4.4 Hz,
1H, 100-Hexo), 2.77 (m, 1H, 70-H), 2.86 (br d, J = 17.6 Hz, 1H, 60-
Hendo), 3.19 (t, J = 6.8 Hz, 2H, 1-H2), superimposed in part 3.20
(dd, J = 17.6 Hz, J0 = 5.2 Hz, 1H, 60-Hexo), 3.46 (m, 1H, 110-H), 4.00
(t, J = 7.2 Hz, 2H, 6-H2), 4.85 (s, +NH, +NH2, NH, NH2), 5.59 (br d,
J = 4.8 Hz, 1H, 80-H), 7.57 (dd, J = 9.2 Hz, J0 = 2.0 Hz, 1H, 20-H), 7.77
(d, J = 2.0 Hz, 1H, 40-H), 8.41 (d, J = 9.2 Hz, 1H, 10-H); 13C NMR
(100.6 MHz, CD3OD) d 23.5 (CH3, 90-CH3), 27.26 (CH, C110), 27.29
(CH2), 27.4 (CH2) (C3, C4), 27.8 (CH, C70), 29.3 (CH2, C130), 29.8
(CH2, C2), 31.2 (CH2, C5), 36.0 (CH2, C60), 36.1 (CH2, C100), 42.4
(CH2, C1), 49.5 (CH2, C6), 115.6 (C, C12a0), 117.6 (C, C11a0), 119.1
(CH, C40), 125.1 (CH, C80), 126.7 (CH, C20), 129.5 (CH, C10), 134.6
(C, C90), 140.2 (C, C30), 141.0 (C, C4a0), 151.3 (C, C5a0), 156.8 (C,
C120), 158.6 (C, guanidine C@N); HRMS (ESI), calcd for (C24H32
35ClN5+H+) 426.2419, found 426.2414.
4.1.2. 1-{9-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methano-
cycloocta[b]quinolin-12-yl)amino]nonyl}guanidine (6e)
It was prepared as described for 6b. From amine 5e (50 mg,
0.12 mmol) and 1H-pyrazole-1-carboxamidine hydrochloride
(21 mg, 0.14 mmol), a brownish solid residue (39 mg) was
obtained. This crude product was taken in MeOH (2 mL) and eluted
through a DowexTM MarathonTM A OH– anion exchange resin (5 g)
using MeOH (500 mL) as the eluent, to provide 6e (33 mg, 59%
yield) as a brownish oil.
6e2HCl: brownish solid; mp 210–211 C; IR (ATR) m 3500–2500
(max at 3250, 3137, 2923, 2852, +NH, NH, CH st), 1630, 1577, 1513
(C@N, Ar–C–C, Ar–C–N st) cm1; 1H NMR (400 MHz, CD3OD) d
1.34–1.48 (complex signal, 10H, 3-H2, 4-H2, 5-H2, 6-H2, 7-H2),
superimposed in part 1.56 (m, 2H, 2-H2), 1.59 (s, 3H, 90-CH3),
1.86 (tt, J = J0 = 7.2 Hz, 2H, 8-H2), 1.93 (br d, J = 17.6 Hz, 1H, 100-
Hendo), superimposed in part 1.94 (dm, J = 12.4 Hz, 1H, 130-Hsyn),
2.09 (dm, J = 12.4 Hz, 1H, 130-Hanti), 2.55 (dd, J = 17.6 Hz, J0 = 4.4 Hz,
1H, 100-Hexo), 2.77 (m, 1H, 70-H), 2.86 (br d, J = 18.0 Hz, 1H, 60-
Hendo), 3.16 (t, J = 7.2 Hz, 2H, 1-H2), 3.21 (dd, J = 18.0 Hz, J0 = 5.6 Hz,
1H, 60-Hexo), 3.45 (m, 1H, 110-H), 3.98 (t, J = 7.2 Hz, 2H, 9-H2), 4.85
(s, +NH, +NH2, NH, NH2), 5.59 (br d, J = 4.4 Hz, 1H, 80-H), 7.56 (dd,
J = 9.2 Hz, J0 = 2.4 Hz, 1H, 20-H), 7.77 (d, J = 2.4 Hz, 1H, 40-H), 8.40
(d, J = 9.2 Hz, 1H, 10-H); 13C NMR (100.6 MHz, CD3OD) d 23.5
(CH3, 90-CH3), 27.3 (CH, C110), 27.7 (CH2), 27.8 [(CH, C70) + CH2]
(C3, C7), 29.3 (CH2, C130), 29.9 (CH2, C2), 30.3 (2CH2), 30.6 (CH2)
(C4, C5, C6), 31.3 (CH2, C8), 36.0 (CH2, C60), 36.1 (CH2, C100), 42.5
(CH2, C1), 49.6 (CH2, C9), 115.7 (C, C12a0), 117.6 (C, C11a0), 119.1
(CH, C40), 125.1 (CH, C80), 126.6 (CH, C20), 129.5 (CH, C10), 134.5
(C, C90), 140.3 (C, C30), 141.0 (C, C4a0), 151.2 (C, C5a0), 156.9 (C,
C120), 158.6 (C, guanidine C@N); HRMS (ESI), calcd for (C27H38
35ClN5+H+) 468.2889, found 468.2903.
4.1.3. 3-Chloro-6,7,10,11-tetrahydro-9-methyl-12-[(3-piperidino-
propyl)amino]-7,11-methanocycloocta[b]quinoline (7)
A mixture of huprine Y, 1 (500 g, 1.76 mmol), finely powdered
KOH (85% purity, 346 mg, 5.24 mmol), and 4 Å molecular sieves
in anhydrous DMSO (4 mL) was stirred, heating every 10 min
approximately with a heat gun for 1 h and at rt for an additional
hour, and then treated with a solution of 1-(3-chloropropyl)piper-
idine hydrochloride (429 mg, 2.17 mmol) in anhydrous DMSO
(2.5 mL). The reaction mixture was stirred at room temperature
overnight, diluted with H2O (50 mL) and extracted with CH2Cl2
(3  25 mL). The combined organic extracts were washed with
H2O (3  100 mL), dried over anhydrous Na2SO4, and evaporated
at reduced pressure to give a yellowish solid (413 mg), which
was purified by column chromatography (40–60 lm silica gel,
CH2Cl2/MeOH/50% aq NH4OH mixtures, gradient elution). On elu-
tion with CH2Cl2/MeOH/50% aq NH4OH 99:1:0.4, piperidinopropy-
lhuprine 7 (35 mg, 5% yield) was isolated as a yellowish oil; Rf 0.38
(CH2Cl2/MeOH/50% aq NH4OH 9:1:0.1).
A solution of 7 (74 mg, 0.18 mmol) in CH2Cl2 (3 mL) was filtered
through a 0.2 lm NYL filter, treated with HCl/Et2O (2.36 N,
0.16 mL, 0.38 mmol), and evaporated under reduced pressure.
The resulting solid was washed with pentane (3  2 mL) to give,
after drying under standard conditions, 72HCl (81 mg) as a pale
yellow solid; mp 189–190 C (dec.); IR (ATR) m 3500–2500 (max
at 3370, 3261, 3070, 2932, +NH, NH, CH st), 1630, 1580, 1513
(Ar–C–C, Ar–C–N st) cm1; 1H NMR (400 MHz, CD3OD) d 1.59 (s,
3H, 9-CH3), superimposed 1.86–1.96 [complex signal, 6H, piperi-
dine 3(5)-H2, piperidine 4-H2], 1.93 (br d, J = 17.2 Hz, 1H, 10-Hendo),
superimposed in part 1.97 (dm, J = 12.4 Hz, 1H, 13-Hsyn), 2.10 (dm,
J = 12.4 Hz, 1H, 13-Hanti), 2.37 (tt, J = 7.6 Hz, J0 = 7.2 Hz, 2H, 20-H2),
2.59 (dd, J = 17.2 Hz, J0 = 4.8 Hz, 1H, 10-Hexo), 2.79 (m, 1H, 7-H),
2.89 (br d, J = 17.6 Hz, 1H, 6-Hendo), 2.90–3.06 [br signal, 2H, piper-
idine 2(6)-Hax], 3.23 (dd, J = 17.6 Hz, J0 = 5.6 Hz, 1H, 6-Hexo), 3.25 (t,
J = 7.6 Hz, 2H, 30-H2), 3.53 (m, 1H, 11-H), 3.50–3.62 [br signal, 2H,
piperidine 2(6)-Heq], 4.08 (t, J = 7.2 Hz, 2H, 10-H2), 4.85 (s, +NH,
NH), 5.59 (br d, J = 4.8 Hz, 1H, 8-H), 7.61 (dd, J = 9.2 Hz, J0 = 2.0 Hz,
1H, 2-H), 7.79 (d, J = 2.0 Hz, 1H, 4-H), 8.41 (d, J = 9.2 Hz, 1H, 1-H);
13C NMR (100.6 MHz, CD3OD) d 22.7 (CH2, piperidine C4), 23.4
(CH3, 9-CH3), 24.2 [2CH2, piperidine C3(5)], 26.0 (CH2, C20), 27.3
(CH, C11), 27.8 (CH, C7), 29.2 (CH2, C13), 36.1 (CH2, C6), 36.3
(CH2, C10), 46.5 (CH2, C10), 54.4 [2CH2, piperidine C2(6)], 55.3
(CH2, C30), 115.8 (C, C12a), 118.3 (C, C11a), 119.2 (CH, C4), 125.1
(CH, C8), 127.1 (CH, C2), 129.2 (CH, C1), 134.6 (C, C9), 140.3 (C,
C3), 140.9 (C, C4a), 151.8 (C, C5a), 156.8 (C, C12); HRMS (ESI), calcd
for (C25H3235ClN3+H+) 410.2358, found 410.2365.
4.1.4. (±)-3-Chloro-6,7,10,11-tetrahydro-9-methyl-12-[(3-morpho-
linopropyl)amino]-7,11-methanocycloocta[b]quinoline (8)
It was prepared as described for 7. From 1 (500 mg, 1.76 mmol)
and 3-morpholinopropyl methanesulfonate (470 mg, 2.10 mmol),
a brownish oily residue (543 mg) was obtained and purified by col-
umn chromatography (40–60 lm silica gel, CH2Cl2/50% aq NH4OH
100:0.4), to give morpholinopropylhuprine 8 (121 mg, 17% yield)
as a yellow oil; Rf 0.42 (CH2Cl2/MeOH/50% aq NH4OH 9:1:0.1).
82HCl: pale yellow solid; mp 173–174 C (dec.); IR (ATR) m
3500–2500 (max at 3384, 3225, 3109, 3048, 2922, 2790, 2728,
2683, 2610, +NH, NH, CH st), 1631, 1582, 1563, 1512 (Ar–C–C,
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Ar–C–N st) cm1; 1H NMR (400 MHz, CD3OD) d 1.59 (s, 3H), 1.93
(br d, J = 17.2 Hz, 1H, 10-Hendo), superimposed in part 1.97 (dm,
J = 12.8 Hz, 1H, 13-Hsyn), 2.10 (dm, J = 12.8 Hz, 1H, 13-Hanti), 2.39
(tt, J = J0 = 7.2 Hz, 2H, 20-H2), 2.59 (dd, J = 17.2 Hz, J0 = 4.8 Hz, 1H,
10-Hexo), 2.78 (m, 1H, 7-H), 2.89 (br d, J = 18.0 Hz, 1H, 6-Hendo),
superimposed 3.12–3.22 (m, 2H, 30-H2), 3.23 (dd, J = 18.0 Hz,
J0 = 5.2 Hz, 1H, 6-Hexo), superimposed with the CD3OD signal
3.28–3.36 [br signal, 2H, morpholine 3(5)-Hax], 3.53 (m, 1H, 11-
H), superimposed 3.46–3.58 (br signal, 2H, morpholine 3(5)-Heq],
3.82–3.93 [br signal, 2H, morpholine 2(6)-Hax], 4.02–4.08 [br sig-
nal, 2H, morpholine 2(6)-Heq], 4.10 (t, J = 7.2 Hz, 2H, 10-H2), 4.85
(s, +NH, NH), 5.59 (br d, J = 4.8 Hz, 1H, 8-H), 7.61 (dd, J = 9.6 Hz,
J0 = 2.0 Hz, 1H, 2-H), 7.79 (d, J = 2.0 Hz, 1H, 4-H), 8.41 (d,
J = 9.6 Hz, 1H, 1-H); 13C NMR (100.6 MHz, CD3OD) d 23.5 (CH3, 9-
CH3), 25.7 (CH2, C20), 27.3 (CH, C11), 27.9 (CH, C7), 29.2 (CH2,
C13), 36.1 (CH2, C6), 36.4 (CH2, C10), 46.5 (CH2, C10), 53.3 [2CH2,
morpholine C3(5)], 55.6 (CH2, C30), 65.1 [2CH2, morpholine C2
(6)], 115.8 (C, C12a), 118.3 (C, C11a), 119.3 (CH, C4), 125.1 (CH,
C8), 127.2 (CH, C2), 129.3 (CH, C1), 134.7 (C, C9), 140.3 (C, C3),
140.9 (C, C4a), 151.8 (C, C5a), 156.9 (C, C12); HRMS (ESI), calcd
for (C24H3035ClN3O+H+) 412.2150, found 412.2164.
4.1.5. 7-[(1,2,3,4-Tetrahydroacridin-9-yl)amino]heptanenitrile
(11c)53
A suspension of tacrine, 9 (1.70 g, 8.57 mmol) and finely pow-
dered KOH (85% purity, 0.97 g, 14.7 mmol), and 4 Å molecular
sieves in anhydrous DMSO (20 mL) was stirred, heating every
10 min approximately with a heat gun for 1 h and at room temper-
ature one additional hour, and then treated with a solution of 7-
bromoheptanenitrile (90% purity, 1.55 mL, 1.96 g, 9.28 mmol) in
anhydrous DMSO (12 mL) dropwise during 30 min. The reaction
mixture was stirred at room temperature overnight, diluted with
5 N NaOH (50 mL) and extracted with EtOAc (3  150 mL). The
combined organic extracts were washed with H2O (4  100 mL),
dried over anhydrous Na2SO4, and evaporated under reduced pres-
sure to give a crude product (2.53 g). Purification of this residue by
column chromatography (40–60 lm silica gel, CH2Cl2/50% aq NH4-
OH 100:0.2) afforded a 85:15 mixture of the dialkylated byproduct
and nitrile 11c (190 mg) and pure nitrile 11c (1.75 g, 66% isolated
yield) as a yellow oil; Rf 0.77 (CH2Cl2/MeOH/50% aq NH4OH
9:1:0.05).
A solution of 11c (79 mg, 0.26 mmol) in CH2Cl2 (15 mL) was
filtered through a 0.2 lm NYL filter, treated with methanolic
HCl (0.53 N, 2.15 mL, 1.14 mmol) and evaporated under reduced
pressure. The resulting solid was taken in MeOH (0.20 mL) and
precipitated by addition of EtOAc (0.60 mL). The precipitate was
washed with pentane (3  2 mL) to give, after drying under stan-
dard conditions, 11cHCl (39 mg) as a pale brown sticky solid; IR
(ATR) m 3500–2500 (max at 3237, 2932, 2860, 2770, +NH, NH, CH
st), 2242 (CN st), 1633, 1586, 1573, 1523 (Ar–C–C, Ar–C–N st)
cm1; 1H NMR (400 MHz, CD3OD) d 1.46–1.54 (complex signal,
4H, 4-H2, 5-H2), 1.66 (tt, J = 7.2 Hz, J0 = 6.8 Hz, 2H, 3-H2), 1.86
(tt, J = 7.2 Hz, J0 = 6.8 Hz, 2H, 6-H2), 1.94–2.02 (complex signal,
4H, 20-H2, 30-H2), 2.44 (t, J = 6.8 Hz, 2H, 2-H2), 2.71 (br t,
J = 5.6 Hz, 2H, 10-H2), 3.02 (br t, J = 6.0 Hz, 2H, 40-H2), 3.97 (t,
J = 7.2 Hz, 2H, 7-H2), 4.85 (s, +NH, NH), 7.59 (dd, J = 8.4 Hz,
J0 = 7.6 Hz, 1H, 70-H), 7.77 (d, J = 8.8 Hz, 1H, 50-H), 7.85 (dd,
J = 8.8 Hz, J0 = 7.6 Hz, 1H, 60-H), 8.40 (d, J = 8.4 Hz, 1H, 80-H); 13C
NMR (100.6 MHz, CD3OD) d 17.2 (CH2, C2), 21.8 (CH2, C30), 23.0
(CH2, C20), 24.9 (CH2, C10), 26.3 (CH2, C3), 26.9 (CH2, C5), 29.30
(CH2), 29.33 (CH2) (C4, C40), 31.2 (CH2, C6), 49.0 (CH2, C7),
112.9 (C, C9a0), 117.1 (C, C8a0), 120.1 (CH, C50), 121.1 (C, C1),
126.3 (CH, C70), 126.5 (CH, C80), 134.1 (CH, C60), 139.8
(C, C10a0), 151.7 (C, C4a0), 158.0 (C, C90); HRMS (ESI), calcd for
(C20H25N3+H+) 308.2121, found 308.2117.
4.1.6. 9-[(1,2,3,4-Tetrahydroacridin-9-yl)amino]nonanenitrile (11e)
It was prepared as described for 11c. From 9 (500 mg,
2.52 mmol) and 9-bromononanenitrile (659 mg, 3.02 mmol), a yel-
lowish oily residue (984 mg) was obtained and purified by column
chromatography (40–60 lm silica gel, CH2Cl2/MeOH/50% aq NH4-
OH mixtures, gradient elution). On elution with CH2Cl2/MeOH/50%
aq NH4OH 99.9:0.1:0.4 to 99.7:0.3:0.4, nitrile 11e (272 mg, 32%
yield) was isolated as a yellow oil; Rf 0.51 (CH2Cl2/MeOH/50% aq
NH4OH 9:1:0.1).
11eHCl: yellow sticky solid; IR (ATR) m 3500–2500 (max at
3268, 2931, 2848, 2756, 2700, 2667, +NH, NH, CH st), 2241 (CN
st), 1630, 1590, 1572, 1522 (Ar–C–C, Ar–C–N st) cm1; 1H NMR
(400 MHz, CD3OD) d 1.34–1.48 (complex signal, 8H, 4-H2, 5-H2,
6-H2, 7-H2), 1.62 (tt, J = J0 = 7.2 Hz, 2H, 3-H2), 1.84 (tt, J = J0 = 7.2 Hz,
2H, 8-H2), 1.94–2.00 (complex signal, 4H, 20-H2, 30-H2), 2.42 (t,
J = 7.2 Hz, 2H, 2-H2), 2.71 (br t, J = 5.6 Hz, 2H, 10-H2), 3.02 (br t,
J = 6.0 Hz, 2H, 40-H2), 3.96 (t, J = 7.2 Hz, 2H, 9-H2), 4.85 (s, +NH,
NH), 7.59 (ddd, J = 8.4 Hz, J0 = 7.2 Hz, J00 = 1.2 Hz, 1H, 70-H), 7.75
(br d, J = 7.6 Hz, 1H, 50-H), 7.85 (ddd, J = 7.6 Hz, J0 = 7.2 Hz,
J00 = 1.2 Hz, 1H, 60-H), 8.40 (br d, J = 8.4 Hz, 1H, 80-H); 13C NMR
(100.6 MHz, CD3OD) d 17.3 (CH2, C2), 21.8 (CH2, C30), 23.0 (CH2,
C20), 24.8 (CH2, C10), 26.3 (CH2, C3), 27.5 (CH2, C7), 29.3 (CH2,
C40), 29.5 (CH2), 29.6 (CH2), 29.9 (CH2) (C4, C5, C6), 31.4 (CH2,
C8), 49.1 (CH2, C9), 112.8 (C, C9a0), 117.0 (C, C8a0), 120.1 (CH,
C50), 121.3 (C, C1), 126.3 (CH, C70), 126.5 (CH, C80), 134.1 (CH,
C60), 139.8 (C, C10a0), 151.7 (C, C4a0), 158.0 (C, C90); HRMS (ESI),
calcd for (C22H29N3+H+) 336.2434, found 336.2436.
4.1.7. 7-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]heptane-
nitrile (12c)53
It was prepared as described for 11c. From 6-chlorotacrine, 10
(2.00 g, 8.59 mmol), and 7-bromoheptanenitrile (90% purity,
1.55 mL, 1.96 g, 9.28 mmol), a yellow oily residue (3.06 g) was
obtained. Purification of this residue by column chromatography
(40–60 lm silica gel, CH2Cl2/50% aq NH4OH 100:0.2) afforded a
87:13 mixture of dialkylated byproduct and nitrile 12c (789 mg)
and pure nitrile 12c (2.06 g, 70% isolated yield) as a yellow oil; Rf
0.92 (CH2Cl2/MeOH/50% aq NH4OH 9:1:0.05).
12cHCl: yellowish solid; mp 86–87 C; IR (ATR) m 3500–2500
(max at 3347, 3138, 3059, 2949, 2928, 2858, 2744, +NH, NH, CH
st), 2245 (CN st), 1639, 1605, 1573, 1524 (Ar–C–C, Ar–C–N st)
cm1; 1H NMR (400 MHz, CD3OD) d 1.46–1.54 (complex signal,
4H, 4-H2, 5-H2), 1.66 (tt, J = 7.2 Hz, J0 = 6.8 Hz, 2H, 3-H2), 1.87 (tt,
J = J0 = 7.2 Hz, 2H, 6-H2), 1.92–2.02 (complex signal, 4H, 20-H2, 30-
H2), 2.45 (t, J = 7.2 Hz, 2H, 2-H2), 2.69 (br t, J = 6.0 Hz, 2H, 10-H2),
3.01 (br t, J = 5.6 Hz, 2H, 40-H2), 3.96 (t, J = 7.2 Hz, 2H, 7-H2), 4.84
(s, +NH, NH), 7.56 (dd, J = 9.2 Hz, J0 = 2.4 Hz, 1H, 70-H), 7.79 (d,
J = 2.4 Hz, 1H, 50-H), 8.39 (d, J = 9.2 Hz, 1H, 80-H); 13C NMR
(100.6 MHz, CD3OD) d 17.2 (CH2, C2), 21.7 (CH2, C30), 22.9 (CH2,
C20), 24.8 (CH2, C10), 26.3 (CH2, C3), 26.9 (CH2, C5), 29.29 (CH2),
29.34 (CH2) (C4, C40), 31.1 (CH2, C6), 49.1 (CH2, C7), 113.4 (C),
115.4 (C) (C8a0, C9a0), 119.1 (CH, C50), 121.2 (C, C1), 126.8 (CH,
C70), 128.8 (CH, C80), 140.1 (CH, C60), 140.5 (C, C10a0), 152.2 (C,
C4a0), 157.8 (C, C90); HRMS (ESI), calcd for (C20H2435ClN3+H+)
342.1732, found 342.1737.
4.1.8. 8-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]octane-
nitrile (12d)
It was prepared as described for 11c. From 6-chlorotacrine, 10
(1.00 g, 4.30 mmol), and 8-bromooctanenitrile (1.01 g, 4.95 mmol),
a yellow oily residue (1.73 g) was obtained. Purification of this
crude by column chromatography (40–60 lm silica gel,
CH2Cl2/50% aq NH4OH 100:0.4), afforded nitrile 12d (411 mg, 27%
yield) as a yellow oil; Rf 0.80 (CH2Cl2/MeOH/50% aq NH4OH
9:1:0.1).
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12dHCl: yellowish solid; mp 210–213 C; IR (ATR) m 3500–
2500 (max at 3251, 3052, 2934, 2853, 2711, +NH, NH, CH st),
2246 (CN st), 1633, 1616, 1588, 1567, 1542, 1517 (Ar–C–C, Ar–
C–N st) cm1; 1H NMR (400 MHz, CD3OD) d 1.40–1.52 (complex
signal, 6H, 4-H2, 5-H2, 6-H2), 1.63 (tt, J = J0 = 7.2 Hz, 2H, 3-H2),
1.85 (tt, J = J0 = 7.2 Hz, 2H, 7-H2), 1.92–2.00 (complex signal, 4H,
20-H2, 30-H2), 2.43 (t, J = 7.2 Hz, 2H, 2-H2), 2.68 (br t, J = 6.0 Hz,
2H, 10-H2), 3.00 (br t, J = 6.0 Hz, 2H, 40-H2), 3.95 (t, J = 7.2 Hz, 2H,
8-H2), 4.85 (s, +NH, NH), 7.57 (dd, J = 9.2 Hz, J0 = 2.0 Hz, 1H, 70-H),
7.77 (d, J = 2.0 Hz, 1H, 50-H), 8.39 (d, J = 9.2 Hz, 1H, 80-H); 13C
NMR (100.6 MHz, CD3OD) d 17.2 (CH2, C2), 21.8 (CH2, C30), 22.9
(CH2, C20), 24.7 (CH2, C10), 26.3 (CH2, C3), 27.4 (CH2, C6), 29.36
(CH2), 29.40 (CH2) (C4, C40), 29.5 (CH2, C5), 31.2 (CH2, C7), 49.2
(CH2, C8), 113.4 (C), 115.5 (C) (C8a0, C9a0), 119.2 (CH, C50), 121.2
(C, C1), 126.8 (CH, C70), 128.8 (CH, C80), 140.1 (CH, C60), 140.6 (C,
C10a0), 152.2 (C, C4a0), 157.8 (C, C90); HRMS (ESI), calcd for
(C21H2635ClN3+H+) 356.1888, found 356.1878.
4.1.9. 9-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]nonane-
nitrile (12e)
It was prepared as described for 11c. From 6-chlorotacrine, 10
(500 mg, 2.15 mmol), and 9-bromononanenitrile (561 mg,
2.57 mmol), a yellow oily residue (849 mg) was obtained and puri-
fied by column chromatography (40–60 lm silica gel, CH2Cl2/
MeOH/50% aq NH4OH mixtures, gradient elution). On elution with
CH2Cl2/MeOH/50% aq NH4OH 100:0:0.4 to 99.8:0.2:0.4, nitrile 12e
(380 mg, 48% yield) was isolated as a yellow oil; Rf 0.82 (CH2Cl2/
MeOH/50% aq NH4OH 9:1:0.1).
12eHCl: yellowish solid; mp 176–177 C; IR (ATR) m 3500–2500
(max at 3248, 3048, 2931, 2852, 2714, +NH, NH, CH st), 2246 (CN
st), 1632, 1589, 1566, 1523 (Ar–C–C, Ar–C–N st) cm1; 1H NMR
(400 MHz, CD3OD) d 1.36–1.50 (complex signal, 8H, 4-H2, 5-H2,
6-H2, 7-H2), 1.62 (tt, J = J0 = 7.2 Hz, 2H, 3-H2), 1.84 (tt, J = J0 = 7.2 Hz,
2H, 8-H2), 1.92–2.02 (complex signal, 4H, 20-H2, 30-H2), 2.43 (t,
J = 7.2 Hz, 2H, 2-H2), 2.68 (br t, J = 6.0 Hz, 2H, 10-H2), 3.00 (br t,
J = 6.4 Hz, 2H, 40-H2), 3.95 (t, J = 7.2 Hz, 2H, 9-H2), 4.85 (s, +NH,
NH), 7.56 (dd, J = 9.2 Hz, J0 = 2.0 Hz, 1H, 70-H), 7.78 (d, J = 2.0 Hz,
1H, 50-H), 8.39 (d, J = 9.2 Hz, 1H, 80-H); 13C NMR (100.6 MHz, CD3-
OD) d 17.3 (CH2, C2), 21.8 (CH2, C30), 22.9 (CH2, C20), 24.7 (CH2, C10),
26.4 (CH2, C3), 27.6 (CH2, C7), 29.3 (CH2, C40), 29.6 (CH2), 29.7
(CH2), 30.0 (CH2) (C4, C5, C6), 31.3 (CH2, C8), 49.2 (CH2, C9),
113.4 (C), 115.5 (C) (C8a0, C9a0), 119.2 (CH, C50), 121.2 (C, C1),
126.8 (CH, C70), 128.8 (CH, C80), 140.1 (CH, C60), 140.5 (C, C10a0), 152.1
(C, C4a0), 157.9 (C, C9’); HRMS (ESI), calcd for (C22H2835ClN3+H+)
370.2045, found 370.2037.
4.1.10. 1-{7-[(1,2,3,4-Tetrahydroacridin-9-yl)amino]heptyl}
guanidine (15c)
It was prepared as described for 6b. From amine 13c (100 mg,
0.32 mmol) and 1H-pyrazole-1-carboxamidine hydrochloride
(57 mg, 0.39 mmol), a brownish solid residue (87 mg) was
obtained. This crude product was taken in MeOH (2 mL) and eluted
through a DowexTM MarathonTM A OH– anion exchange resin (5 g)
using MeOH (500 mL) as the eluent, to provide guanidine 15c
(81 mg, 72% yield) as a brownish oil.
15c2HCl: brownish sticky solid; IR (ATR) m 3500–2500 (max at
3257, 3132, 2930, 2858, +NH, NH, CH st), 1631, 1574, 1520 (C@N,
Ar–C–C, Ar–C–N st) cm1; 1H NMR (400 MHz, CD3OD) d 1.38–
1.50 (complex signal, 6H, 3-H2, 4-H2, 5-H2), 1.59 (tt, J = J0 = 6.8 Hz,
2H, 2-H2), 1.86 (tt, J = J0 = 7.2 Hz, 2H, 6-H2), 1.92–2.02 (complex sig-
nal, 4H, 20-H2, 30-H2), 2.71 (br t, J = 5.2 Hz, 2H, 10-H2), 3.02 (t,
J = 5.6 Hz, 2H, 40-H2), 3.16 (t, J = 6.8 Hz, 2H, 1-H2), 3.96 (t,
J = 7.2 Hz, 2H, 7-H2), 4.85 (s, +NH, +NH2, NH, NH2), 7.59 (ddd,
J = 8.4 Hz, J0 = 6.8 Hz, J00 = 1.6 Hz, 1H, 70-H), 7.76 (dd, J = 8.4 Hz,
J0 = 1.6 Hz, 1H, 50-H), 7.86 (ddd, J = 8.4 Hz, J0 = 6.8 Hz, J00 = 1.2 Hz, 1H,
60-H), 8.40 (br d, J = 8.4 Hz, 1H, 80-H); 13C NMR (100.6 MHz, CD3OD)
d 21.8 (CH2, C30), 23.0 (CH2, C20), 24.9 (CH2, C10), 27.57 (CH2), 27.63
(CH2) (C3, C5), 29.3 (CH2, C40), 29.8 (CH2), 29.9 (CH2) (C2, C4), 31.5
(CH2, C6), 42.4 (CH2, C1), 49.1 (CH2, C7), 112.8 (C, C9a0), 117.0 (C,
C8a0), 120.1 (CH, C50), 126.3 (CH, C70), 126.5 (CH, C80), 134.1 (CH,
C60), 139.8 (C, C10a0), 151.7 (C, C4a0), 158.0 (C, C90), 158.5 (C, guani-
dine C@N); HRMS (ESI), calcd for (C21H31N5+H+) 354.2652, found
354.2665.
4.1.11. 1-{9-[(1,2,3,4-Tetrahydroacridin-9-yl)amino]nonyl}guan-
idine (15e)
It was prepared as described for 6b. From 13eHCl (47 mg,
0.12 mmol) and 1H-pyrazole-1-carboxamidine hydrochloride
(21 mg, 0.14 mmol), a brownish solid residue (46 mg) was
obtained. This crude product was taken in MeOH (2 mL) and eluted
through a DowexTM MarathonTM A OH– anion exchange resin (5 g)
using MeOH (500 mL) as the eluent, to provide guanidine 15e
(35 mg, 76% yield) as a brownish oil.
15e2HCl: brownish sticky solid; IR (ATR) m 3500–2500 (max at
3256, 3132, 2926, 2852, +NH, NH, CH st), 1661, 1631, 1575, 1521
(C@N, Ar–C–C, Ar–C–N st) cm1; 1H NMR (400 MHz, CD3OD) d
1.34–1.48 (complex signal, 10H, 3-H2, 4-H2, 5-H2, 6-H2, 7-H2),
1.58 (tt, J = J0 = 6.8 Hz, 2H, 2-H2), 1.84 (tt, J = J0 = 7.2 Hz, 2H, 8-H2),
1.94–2.00 (complex signal, 4H, 20-H2, 30-H2), 2.70 (br t, J = 6.0 Hz,
2H, 10-H2), 3.02 (br t, J = 6.4 Hz, 2H, 40-H2), 3.16 (t, J = 6.8 Hz, 2H,
1-H2), 3.95 (t, J = 7.2 Hz, 2H, 9-H2), 4.85 (s, +NH, +NH2, NH, NH2),
7.59 (ddd, J = 8.8 Hz, J0 = 6.8 Hz, J00 = 1.2 Hz, 1H, 70-H), 7.76 (dd,
J = 8.4 Hz, J0 = 1.2 Hz, 1H, 50-H), 7.85 (ddd, J = 8.4 Hz, J0 = 6.8 Hz,
J00 = 1.2 Hz, 1H, 60-H), 8.40 (br d, J = 8.8 Hz, 1H, 80-H); 13C NMR
(100.6 MHz, CD3OD) d 21.8 (CH2, C30), 22.9 (CH2, C20), 24.9 (CH2,
C10), 27.6 (2CH2, C3, C7), 29.3 (CH2, C40), 29.8 (CH2, C2), 30.1
(2CH2), 30.4 (CH2) (C4, C5, C6), 31.5 (CH2, C8), 42.4 (CH2, C1),
49.1 (CH2, C9), 112.8 (C, C9a0), 116.9 (C, C8a0), 120.1 (CH, C50),
126.3 (CH, C70), 126.4 (CH, C80), 134.1 (CH, C60), 139.7 (C, C10a0),
151.6 (C, C4a0), 157.9 (C, C90), 158.5 (C, guanidine C@N); HRMS
(ESI), calcd for (C23H35N5+H+) 382.2965, found 382.2975.
4.1.12. 1-{9-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]
nonyl}guanidine (16e)
It was prepared as described for 6b. From 14eHCl (90 mg,
0.22 mmol) and 1H-pyrazole-1-carboxamidine hydrochloride
(39 mg, 0.27 mmol), a brownish solid residue (81 mg) was
obtained. This crude product was taken in MeOH (2 mL) and eluted
through a DowexTM MarathonTM A OH anion exchange resin (5 g)
using MeOH (500 mL) as the eluent, to provide guanidine 16e
(61 mg, 67% yield) as a brownish oil.
16e2HCl: brownish solid; mp 209–210 C; IR (ATR) m 3500–
2500 (max at 3253, 3126, 2928, 2855, +NH, NH, CH st), 1631,
1572, 1514 (C@N, Ar–C–C, Ar–C–N st) cm1; 1H NMR (400 MHz,
CD3OD) d 1.38–1.52 (complex signal, 10H, 3-H2, 4-H2, 5-H2, 6-H2,
7-H2), 1.60 (tt, J = J0 = 6.8 Hz, 2H, 2-H2), 1.86 (tt, J = J0 = 7.2 Hz, 2H,
8-H2), 1.92–2.02 (complex signal, 4H, 20-H2, 30-H2), 2.68 (br t,
J = 6.0 Hz, 2H, 10-H2), 3.00 (br t, J = 6.0 Hz, 2H, 40-H2), 3.17 (t,
J = 6.8 Hz, 2H, 1-H2), 3.95 (t, J = 7.2 Hz, 2H, 9-H2), 4.85 (s, +NH,
+NH2, NH, NH2), 7.57 (dd, J = 9.2 Hz, J0 = 2.4 Hz, 1H, 70-H), 7.79 (d,
J = 2.4 Hz, 1H, 50-H), 8.40 (d, J = 9.2 Hz, 1H, 80-H); 13C NMR
(100.6 MHz, CD3OD) d 21.8 (CH2, C30), 22.9 (CH2, C20), 24.8 (CH2,
C10), 27.5 (CH2), 27.6 (CH2) (C3, C7), 29.3 (CH2, C40), 29.7 (2CH2),
29.8 (2CH2) (C2, C4, C5, C6), 31.3 (CH2, C8), 42.4 (CH2, C1), 49.2
(CH2, C9), 113.3 (C), 115.4 (C) (C8a0, C9a0), 119.1 (CH, C50), 126.8
(CH, C70), 128.8 (CH, C80), 140.0 (CH, C60), 140.4 (C, C10a0), 152.1
(C, C4a0), 157.7 (C, C90), 158.6 (C, guanidine C@N); HRMS (ESI),
calcd for (C23H3435ClN5+H+) 416.2576, found 416.2589.
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4.2. Biological assays
4.2.1. T. brucei culturing and evaluation of antitrypanosomal
activity
Bloodstream form T. brucei (strain 221) was cultured at 37 C in
modified Iscove’s medium.54 Trypanocidal activity was assessed by
growing parasites in the presence of various concentrations of the
novel compounds and determining the levels which inhibited
growth by 50% (IC50) and 90% (IC90). T. brucei in the logarithmic
phase of growth were diluted back to 2.5  104 mL1 and aliquoted
into 96-well plates. The compounds were then added at a range of
concentrations and the plates incubated at 37 C. Each drug con-
centration was tested in triplicate. Resazurin was added after
48 h and the plates incubated for a further 16 h and the plates then
read in a Spectramax plate reader. Results were analysed using
GraphPad Prism.
4.2.2. Cytotoxic activity against rat skeletal myoblast L6 cells
Cytotoxicity against mammalian cells was assessed using
microtitre plates following a described procedure.55 Briefly, rat
skeletal muscle L6 cells were seeded at 1  104 mL1 in 200 lL
of growth medium containing different compound concentra-
tions. The plates were incubated for 6 days at 37 C and 20 lL
resazurin was then added to each well. After a further 8 h incu-
bation, the fluorescence was determined using a Spectramax
plate reader.
4.2.3. Acetylcholinesterase inhibitory activity
The inhibitory activity against Electrophorus electricus (Ee) AChE
(Sigma–Aldrich) was evaluated spectrophotometrically by the
method of Ellman et al.56 The reactions took place in a final volume
of 300 lL of 0.1 M phosphate-buffered solution pH 8.0, containing
EeAChE (0.03 U/mL) and 333 lM 5,50-dithiobis(2-nitrobenzoic)
acid (DTNB; Sigma–Aldrich) solution used to produce the yellow
anion of 5-thio-2-nitrobenzoic acid. Inhibition curves were per-
formed in duplicates using at least 10 increasing concentrations
of inhibitors and preincubated for 20 min at 37 C before adding
the substrate. One duplicate sample without inhibitor was always
present to yield 100% of AChE activity. Then substrate, acetylthio-
choline iodide (450 lM; Sigma–Aldrich), was added and the reac-
tion was developed for 5 min at 37 C. The colour production was
measured at 414 nm using a labsystems Multiskan
spectrophotometer.
Data from concentrationinhibition experiments of the inhibi-
tors were calculated by non-linear regression analysis, using the
GraphPad Prism program package (GraphPad Software; San
Diego, USA), which gave estimates of the IC50 (concentration of
drug producing 50% of enzyme activity inhibition). Results are
expressed as mean ± SEM of at least 4 experiments performed
in duplicate.
4.2.4. Determination of brain permeability: PAMPA-BBB assay
The in vitro permeability (Pe) of the novel compounds and four-
teen commercial drugs through lipid extract of porcine brain mem-
brane was determined by using a parallel artificial membrane
permeation assay.45 Commercial drugs and the target compounds
were tested using a mixture of PBS/EtOH 70:30. Assay validation
was made by comparing experimental and described permeability
values of the commercial drugs (Table 3), which showed a good
correlation: Pe (exp) = 1.6079 Pe (lit)  1.2585 (R2 = 0.9217). From
this equation and the limits established by Di et al. for BBB perme-
ation, three ranges of permeability were established: compounds
of high BBB permeation (CNS+): Pe (106 cm s1) > 5.17; com-
pounds of low BBB permeation (CNS): Pe (106 cm s1) < 1.95;
and compounds of uncertain BBB permeation (CNS±): 5.17 > Pe
(106 cm s1) > 1.95.
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Hydrocortisone 1.9 1.4 ± 0.1
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Promazine 8.8 13.8 ± 0.3
Progesterone 9.3 16.8 ± 0.3
Desipramine 12.0 17.8 ± 0.1
Testosterone 17.0 26.5 ± 0.4
Verapamil 16.0 28.4 ± 0.5
a Taken from Ref. 45.
b Values are expressed as the mean ± SD of three independent experiments.
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